IFNB1 and myeloid sarcoma: The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing‐remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care.